Table 2.
Demographic and Treatment Characteristics by Baseline Smoking Status at Trial Enrollment
| Variable | Never –smoker N=155 |
Former- smoker*,x N=1167 |
Current- smokert N=160 |
P-value | |
|---|---|---|---|---|---|
| Median Age (Yrs) | 59 | 62 | 56 | p < 0.001 | |
| Female | 114 (74%) | 539 (46%) | 92 (58%) | p < 0.001 | |
| Race | p < 0.001 | ||||
| White | 114 (76%) | 1043 (90%) | 131 (83%) | ||
| Black | 20 (13%) | 84 (7%) | 25 (16%) | ||
| Asian | 17 (11%) | 18 (2%) | 1 (<1%) | ||
| Hawaiian | - | 5 (<1%) | - | ||
| Native American | - | 5 (<1%) | 1 (<1%) | ||
| Missing/Unknown/Not reported | 4 | 12 | 2 | ||
| Ethnicity | p = 0.004 | ||||
| Hispanic | 12 (8%) | 33 (3%) | 3 (2%) | ||
| Non-Hispanic | 138 (92%) | 1064 (97%) | 150 (98%) | ||
| Missing/Unknown/Not reported | 5 | 70 | 7 | ||
| >5% Weight loss in Previous 6 Months | 23 (15%) | 239 (21%) | 44 (28%) | p = 0.02 | |
| Median BMI | 27.1 | 26.9 | 23.9 | p < 0.001 | |
| Months from Surgery to Randomization (median, IQR) | 1.63 [1.45, 1.94] | 1.68 [1.45, 2.04] | 1.77 [1.51, 2.14] | p = 0.054 | |
| Study Assigned Treatment Arm | p = 0.76 | ||||
| Arm A (Chemo.) | 81 (52%) | 581 (50%) | 77 (48%) | ||
| Arm B (Chemo. + Bev.) | 74 (48%) | 586 (50%) | 83 (52%) | ||
| Bevacizumab Dose Modifications | No | 24 | 194 | 29 | p = 0.95 |
| Yes | 49 | 381 | 50 | ||
| Total | 73 | 575 | 79 | ||
| Chemotherapy Dose Modifications | No | 65 | 521 | 70 | p = 0.75 |
| Yes | 89 | 624 | 86 | ||
| Total | 154 | 1145 | 156 | ||
| Median number of Bevacizumab cycles | 8 | 9 | 12 | p = 0.36 | |
| Median number of Chemotherapy cycle | 4 | 4 | 4 | p = 0.29 |
*
Quit smoking prior to study enrollment
x
9 patients among 1176 patients who reported not smoking at baseline were never smokers who were not expected to complete the details about baseline smoking status.
t
17 patients among 1344 patients who reported ever smoking in their lifetime did not complete the question about smoking at baseline and could therefore not be classified as current or former smokers.